John McCamant joined the leading investment newsletter, Medical Technology Stock Letter, as an associate editor in 1987 and was named editor in August 2000. He has spent over 35 years on the front lines of biotechnology investing. In his previous role as an equities analyst for the American Healthcare fund, Mr. McCamant uncovered investment opportunities and guided investment strategy.
The Fruits of biotech have never been more visible, with vaccines, obesity drugs, and first-in-class disease-modifying treatments in cancer and immunology, not to mention the advancements in CRISPR and cell engineering that could prove disruptive over the next decade.